0800_Garcia.pdf

1、Antiplatelet and antithrombotic therapy in CLTILawrence A.Garcia,MDDirector,Vascular ServicesSt.Francis Hospital and Heart CenterCatholic Health Services,Long IslandRoslyn,NYDisclosure Statement of Financial InterestGrant/Research SupportConsulting(non-compensated)Major Stock Shareholder/EquityRoyal

2、ty IncomeOwnership/FounderIntellectual Property RightsOther Financial BenefitAbbott,MedtronicMedtronic,Boston Scientific,Abbott,PhillipsPrimacea,TissueGen,Orchestra,R3 Vascular,Transit Medical,Syntervention,CagentNone Innovation Vascular PartnersNone None Within the past 12 months,I or my spouse/par

3、tner have had a financial interest/arrangement or affiliation with the organization(s)listed below.Affiliation/Financial RelationshipCompanyGeneral considerations Anti-platelet Statin ACE-I/ARB Glycemic control Tobacco cessation Local foot careGeneral considerations Anti-platelet Statin ACE-I/ARB Gl

4、ycemic control Tobacco cessation Local foot careAnti-platelet Current guidelines still recommend ASA or P2Y12 therapyAHA guidelines 2016Hirsh,J,Bhatt,DL.Comparitive benefits of clopidogrel and aspirin in high risk patient populations.Arch Intern Med 2004Caprie steering comte.Lancet 1996AHA guideline

5、s for PAD 2024Bonaca et al NEJM 2020;382:1994-2004Summary Clearly primary/secondary prevention are critical methods of therapy for our patients with atherosclerosis General guidelines advocate Class 1,LOE A for antiplatelet/antithrombotic therapies for benefit of patients to include life and limb Pr

6、imary and secondary treatments in combination with revascularization strategies offer the best options for our patients with significant symptomatic PVDAntiplatelet and antithrombotic therapy in CLTILawrence A.Garcia,MDDirector,Vascular Ser